Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Psychedelic therapy at a crossroads at the dawn of 2023

By Brian Buntz | December 30, 2022

psychedelic

[Image courtesy of Erin Williamson under the Creative Commons License via Flickr]

In several ways, psychedelic therapy continued to make strides toward legitimization in 2022. Michael Pollan’s best-selling psychedelic treatise “How to Change Your Mind” formed the basis for a popular Netflix series. Several celebrities declared that psychedelics had improved their lives.

Decriminalization efforts gaining steam

Colorado decriminalized psychedelic plants, as did the city of San Francisco. (Several other U.S. cities have done so earlier.) On January 1, 2023, Oregon will authorize therapy based on the magic mushroom compound psilocybin under Ballot Measure 109, which passed in November 2020. The state will restrict the treatment to licensed facilities with therapists with specific training. In 2023, New York state and California could legalize natural psychedelics. In Canada, Quebec became the first province to authorize insurance coverage for psilocybin-based psychotherapy.

2022 was a bad year for public psychedelic therapy companies

Big Pharma’s decision to stay away from psychedelics seems to have been sound — at least in 2022. The year was rough for many companies aiming to develop psychedelics for mood disorders.

  • In 2022, the psilocybin-focused company COMPASS Pathways (Nasdaq:CMPS) saw its stock fall 66%.
  • The psychedelic company ATAI Life Sciences also saw its shares fall by 66%.
  • Some companies fared worse. Cybin (NYSEAMERICAN: CYBN), Numinus Wellness (TSE:NUMI) and Revive Therapeutics (OTCMKTS:RVVTF) saw their stock price dip more than 70% over the year.
  • MindMed (Nasdaq:MNMD) saw its share price plunge 90%. In June, the company received a notice of potential delisting from the Nasdaq.

For comparison, the Nasdaq Biotechnology Index fell 13% over 2022 while the Dow Jones U.S. Pharmaceuticals Index ticked up 4%. That said, 2022 was the worst year for stocks overall since 2008.

Clinical trial progress

Compass Pathways is currently running the first Phase 3 study for psilocybin — as a potential therapy for treatment-resistant depression. In November 2022, NEJM published an article describing the results of the company’s Phase 2b study evaluating a single dose of psilocybin for treatment-resistant depression. A single 25-mg dose reduced Montgomery–Åsberg Depression Rating Scale scores significantly. Still, the authors note that more extensive and longer clinical trials would be required to determine the safety and efficacy of psilocybin in depression.

In November, MAPS announced that it had completed a second Phase 3 “MAPP2” study of MDMA-assisted therapy to treat PTSD. It anticipates top-line data to be ready in the first quarter of 2023.

According to a leaked letter, the U.S. government is reportedly mulling approving psilocybin and MDMA in the coming years.

Psychedelic therapy risks

There are inherent risks involved in attempting to commercialize psychedelics, which remain Schedule I substances in the U.S. According to the DEA, they have no legitimate medical use, lack of safety for use with medical supervision and high abuse liability. In addition, psychedelics’ Schedule I status makes research difficult.

There continues to be a considerable degree of psychedelic hype, but the drug class come with adverse events. The potential widespread availability of psychedelics will lead to accidents and suicides, said veteran psychedelic researcher Dr. Rick Strassman in an interview in October.  “Another Charles Manson could crawl out of the swamp,” Strassman said. “It behooves academics and pharma to keep the lid on their unbridled enthusiasm [for psychedelics].”

It is also difficult to have strong patent protection for classic psychedelics like psilocybin. The Harvard Law Review notes that the U.S. Patent and Trademark Office (PTO) does not have substantial experience evaluating psychedelic compounds. In addition, patenting psychedelic therapies could “promote biopiracy, the exploitation of Indigenous knowledge without compensation,” the publication noted.

An evolving reputation?

As we noted in August, psychedelics also continue to have a reputational problem. For example, a 2021 Hill-HarrisX survey found that 65% of the public thought psychedelics had no legitimate medical use. Support was higher, however, for patients with mood disorders, according to a separate survey conducted by The Harris Poll on behalf of the ketamine company Delic Holdings. That survey found that 65% of Americans believed drugs such as ketamine, psilocybin and MDMA should be made available to patients with treatment-resistant anxiety, depression or PTSD.

But public support for decriminalization is also building. An article in JAMA Psychiatry noted that between January 2019 to September 2022, there was a sevenfold increase in proposed decriminalization bills introduced. There have been 74 bills and referendums in 25 states in that timeframe. Of those, 10 bills were enacted. Another 32 remained active at the time of publication. The authors of the JAMA article project that most U.S. states could legalize psychedelics from 2034 to 2037 based on an analytic model related to marijuana legalization.

The growing legalization efforts could mean that natural psychedelics follow a course similar to cannabis, which is legal for recreational or medical use in most U.S. states.


Filed Under: Psychiatric/psychotropic drugs
Tagged With: psychedelic therapy
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
depression sadness and loneliness concept art illustration of wo
Precision psychiatry: A data-driven approach to personalized depression treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE